Written by Peter Orpen  |  For educational purposes only  |  Individual results may vary

Lion's Mane and Ashwagandha: The Build-and-Protect Stack

Two well-studied adaptogens. Complementary mechanisms. A case for using them together — with the evidence clearly laid out.

The Stress-Cognition Problem

Chronic stress does not just make you feel worse — it physically degrades the brain structures responsible for learning and memory. Sustained elevation of cortisol, the body's primary stress hormone, is associated with reduced hippocampal volume, impaired neuroplasticity, and measurable declines in working memory and executive function.

This creates a compounding cycle. Stress impairs cognitive function. Impaired cognitive function makes work and daily demands harder to manage. Harder demands generate more stress. Breaking into that cycle from a single point of intervention is difficult.

Two compounds with solid human trial evidence are increasingly discussed together for this reason: Lion's Mane mushroom (Hericium erinaceus) and ashwagandha (Withania somnifera). They act through different mechanisms, and that difference is precisely the point.

This article covers the evidence for each compound separately, explains why the mechanistic case for stacking them is reasonable, and sets out practical guidance for timing and dosing. It also names the important limitations — including the fact that no human trial has tested this combination directly.

Different Mechanisms, Complementary Roles

Lion's Mane: The NGF Pathway

Lion's Mane contains two families of compounds unique to this species — hericenones and erinacines — that have been shown in preclinical research to cross the blood-brain barrier and stimulate the synthesis of nerve growth factor (NGF). NGF is a protein critical to the maintenance, survival, and regeneration of neurons, particularly in the hippocampus and prefrontal cortex (PMID: 34865649).

The significance of this pathway is that it supports neuroplasticity: the brain's capacity to form new connections, repair damaged ones, and adapt to new demands. In animal models, Lion's Mane supplementation has been associated with increased NGF expression and improved maze-learning performance. Human trials have now begun to substantiate some of these early signals.

Ashwagandha: The HPA Axis

Ashwagandha works through a fundamentally different route. Its primary bioactives — withanolides, particularly withaferin A — modulate the hypothalamic-pituitary-adrenal (HPA) axis, the neuroendocrine system that governs the body's stress response. In practical terms, ashwagandha has consistently demonstrated the capacity to lower serum cortisol levels in human trials.

This matters because cortisol, when chronically elevated, is neurotoxic. It suppresses BDNF (brain-derived neurotrophic factor), impairs hippocampal neurogenesis, and interferes with synaptic plasticity — the very processes that Lion's Mane is acting to support.

The "build and protect" framing captures this division of labour: Lion's Mane builds neural capacity through the NGF pathway; ashwagandha protects that capacity by reducing cortisol-driven stress damage to the brain.

Human Evidence: Lion's Mane

The most widely cited Lion's Mane RCT enrolled 30 adults with mild cognitive impairment (MCI). Participants received 3g/day of Lion's Mane powder over 16 weeks. Compared to placebo, the treatment group showed significant improvement on cognitive function scales. When supplementation ended, scores declined — a finding the authors interpreted as consistent with an ongoing, dose-dependent mechanism (PMID: 18844328, n = 30).

A more recent randomised controlled trial enrolled 41 healthy adults and used a lower dose of 1.8g/day over 28 days. Participants in the treatment group reported statistically significant reductions in stress and anxiety compared to placebo. Notably, no significant effect on processing speed was observed, which the authors noted as a limitation. This suggests that the cognitive effects of Lion's Mane may be more relevant to subjective wellbeing and stress-related impairment than to raw processing performance in healthy younger populations (PMID: 38004235, n = 41).

Both studies are small, and the field would benefit from larger, longer trials. The mechanistic basis — NGF stimulation through hericenones and erinacines — is well-characterised in preclinical work, but translating animal findings to human outcomes always requires caution (PMID: 34865649).

Read the full Lion's Mane evidence review for a deeper treatment of the research landscape.

Human Evidence: Ashwagandha

Ashwagandha has one of the larger bodies of human trial evidence among adaptogens. A 2012 double-blind RCT enrolled 64 adults with a history of chronic stress and administered KSM-66 ashwagandha at 300mg/day for 60 days. The treatment group showed significantly reduced serum cortisol, lower scores on the Perceived Stress Scale (PSS), and reduced anxiety compared to placebo (PMID: 23439798, n = 64).

A 2020 RCT replicated these cortisol findings at a lower dose: 240mg/day over 60 days in 58 adults produced statistically significant reductions in cortisol and self-reported stress (PMID: 32021735, n = 58).

A separate 2020 RCT examined cognitive outcomes specifically, using 600mg/day over 8 weeks in 60 adults. Significant improvements were observed in memory and executive function relative to placebo, with the authors suggesting that these cognitive effects may be downstream of HPA axis normalisation — that is, cognitive function improved partly because stress decreased (PMID: 31975506, n = 60).

These findings are supported at the review level: a meta-analysis examining anxiolytic effects across multiple human RCTs confirmed that ashwagandha consistently produces statistically significant reductions in anxiety and stress measures compared to placebo (PMID: 28471731). This is not a compound with a preliminary evidence base — the cortisol and stress-reduction effects are replicated across independent trials.

For the full picture, see the Lion's Mane vs Ashwagandha comparison.

The Case for Stacking: Build and Protect

To be direct about the evidence gap: no human study has examined Lion's Mane and ashwagandha administered together. The stack rationale is mechanistic inference — a reasoned argument based on how each compound acts, not a finding from a controlled trial. That distinction matters, and it should inform how you weigh this section relative to the individual compound evidence above.

With that caveat clearly stated, the mechanistic case is coherent. Chronic cortisol elevation impairs the very neuroplasticity processes that Lion's Mane appears to support. If ashwagandha successfully reduces cortisol — which multiple RCTs suggest it does — it removes a brake on neural repair and adaptation. Lion's Mane, acting simultaneously through the NGF pathway, supplies a positive signal for neural growth. The two compounds address what might be described as opposite sides of the same problem: one reducing interference (cortisol), one increasing a growth signal (NGF).

This is not a claimed synergy in the pharmacological sense. It is a case for why the compounds are complementary rather than redundant, and why using both may be more effective than either alone — not because of interaction effects, but because of non-overlapping mechanisms.

For a detailed discussion of how Lion's Mane fits into a broader stress management approach, see Lion's Mane for stress.

Practical Guidance: Dosing and Timing

Both compounds benefit from consistent daily use over extended periods. The 16-week Lion's Mane trial (PMID: 18844328) reported that cognitive improvements declined when supplementation ended — suggesting ongoing use is needed to sustain effects. Similarly, ashwagandha cortisol reductions in the published trials were observed after 60 days of consistent use.

Neither compound is intended as an acute or as-needed intervention. This is important to communicate to anyone approaching these supplements with a pharmaceutical mindset.

A Note on Ashwagandha Forms

The majority of ashwagandha human trials have used standardised root extracts (KSM-66 or Sensoril), typically at 240–600mg/day. Ashwagandha root powder — the whole dried root — requires higher gram doses to achieve comparable withanolide concentrations. If using root powder rather than extract, dosing guidance from the product label should be followed, as potency varies significantly between preparations.

Teelixir Products for This Stack

Teelixir produces both compounds as certified organic powders. Both are ACO (Australian Certified Organic) certified.

Organic Lion's Mane Mushroom Powder — sourced from di tao growing regions, dual-extracted to concentrate the active hericenones and erinacines. Suitable for adding to coffee, matcha, or warm water in the morning.

Organic Ashwagandha Root Powder — whole root powder from certified organic sources. Can be taken morning or evening, blended into warm milk or a smoothie. Those sensitive to the earthy flavour may find it easier in a recipe context rather than plain water.

Both products are available without fillers, binders, or flow agents — just the single ingredient.

Who This Stack May Suit

Based on the profiles of participants in published trials, this combination may be worth considering for:

• Adults experiencing chronic work-related or lifestyle stress with associated cognitive fatigue
• Those noticing age-related changes in memory, focus, or mental clarity
• People who have addressed sleep and exercise foundations and are looking for adjunct nutritional support
• Individuals who want a dual-mechanism approach that addresses both neural repair and stress regulation

It is less likely to be appropriate as a standalone intervention for clinical anxiety, diagnosed cognitive impairment, or where pharmaceutical treatment is indicated. These compounds are dietary supplements, not medicines. Anyone with a known health condition, or taking prescription medication (particularly thyroid medications or sedatives, with which ashwagandha may interact), should consult a qualified healthcare practitioner before beginning supplementation.

Individual results may vary. The published trials document group-level averages — not everyone responds identically, and some participants in published studies showed no measurable effect.

Frequently Asked Questions

Author: Peter Orpen  |  Teelixir Editorial  |  Published 2026